An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice
A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoNorm® in the Treatment of Type 2 Diabetic Patients in Routine Clinical Practice
1 other identifier
observational
30,554
1 country
1
Brief Summary
This study is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy, safety and convenience of using repaglinide (NovoNorm®) in type 2 diabetes management in routine clinical practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2004
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2004
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2006
CompletedFirst Submitted
Initial submission to the registry
December 21, 2011
CompletedFirst Posted
Study publicly available on registry
December 26, 2011
CompletedOctober 28, 2016
October 1, 2016
1.9 years
December 21, 2011
October 26, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
HbA1c (glycosylated haemoglobin)
Secondary Outcomes (4)
Fasting Plasma Glucose (FPG)
Postprandial glucose values
Incidence of hypoglycaemia
Adverse drug reactions (ADR)
Study Arms (1)
Repaglinide
Interventions
Prescription according to the product labelling at the physicians' discretion
Eligibility Criteria
Patients with type 2 diabetes, newly diagnosed or not adequately controlled on their current therapy, who are treated repaglinide by their physicians in accordance with the approved labeling
You may qualify if:
- Type 2 diabetes
- Newly diagnosed or not adequately controlled with current therapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Novo Nordisk A/Slead
Study Sites (1)
Novo Nordisk Investigational Site
Istanbul, 34335, Turkey (Türkiye)
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Global Clinical Registry (GCR, 1452)
Novo Nordisk A/S
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 21, 2011
First Posted
December 26, 2011
Study Start
August 1, 2004
Primary Completion
July 1, 2006
Study Completion
July 1, 2006
Last Updated
October 28, 2016
Record last verified: 2016-10